Data / Form D filings / Vivaldi Biosciences Inc
Vivaldi Biosciences Inc: Form D filing
Vivaldi Biosciences Inc, a biotechnology company in New York, NY, filed a Form D with the SEC in 2010. The latest, on July 7, 2010, reports $2 million sold of an offering with no set size to 4 investors.
Find out what Vivaldi Biosciences Inc does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- BELLEVUE HOSPITAL CENTER, 462 First Avenue, Bldg. A, Ste. 908, New York, NY, 10016
- Phone
- (646) 381-6680
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2006
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506
- SEC identifier (CIK)
- 1398022
The full lists. Form D filings in New York: 4,357 rows, $123.57, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jul 7, 2010 | New notice | Indefinite | $1,974,546 | Indefinite | 4 | Jul 2, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Douglass Given | Executive Officer, Director | |
| Elliott O. Kieff, M.D. | Promoter | |
| N/A O. Bay City Capital Fund IV Co-Investment Fund, L.P. | Promoter | |
| Vic Schmitt | Director | |
| William Gerber | Director | |
| N/A O. Bay City Capital Fund IV, L.P. | Promoter | |
| Georg Nebgen | Director | |
| Peter O. Palese, Ph.D. | Promoter | |
| N/A O. Scheer Investment Holdings IX LLC | Promoter | |
| Peter Johann | Director | |
| William O. Wick, Jr. | Executive Officer, Promoter | |
| David Liebowitz | Executive Officer, Promoter | |
| N/A O. Douglass B. and Kim Given Revocable Trust, U/A/D 8/11/01 | Promoter | |
| Adolfo O. Garcia-Sastre, Ph.D. | Promoter |
Other biotechnology companies in New York that filed recently
- Swep Bio, Inc. $2.5 million · Oct 29, 2026
- Hypercell Technologies Inc. $3 million · Oct 14, 2026
- CAD Therapeutics, Inc. $4 million · Oct 2, 2026
- Vicora, Inc. $2.3 million · Sep 18, 2026
- GevRx Nutraceuticals, Inc. $300,000 · Sep 18, 2026
- Episteme Prognostics, Inc. $5.1 million · Sep 4, 2026
Every Form D from the week of Jul 5, 2010 · All recent filings in New York · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Vivaldi Biosciences Inc reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.